Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Home
About
Overview
Open Source Software
Help
History (1)
Shapiro, Geoffrey
See All Pages
Find People
Find Everything
Login
to
edit your profile
(add a photo, education, awards, etc.), search
student opportunities
, and
create reports
.
Edit My Profile
My Person List (
0
)
Opportunity Search
Return to Top
Geoffrey Ira Shapiro, M.D., Ph.D.
Title
Professor of Medicine
Institution
Dana-Farber Cancer Institute
Department
Medicine
Address
Dana-Farber Cancer Institute
Medical Oncology - Mayer 446
450 Brookline Ave
Boston MA 02215
Phone
617/632-4942
Fax
617/632-1977
vCard
Download vCard
(
login for email
)
research activities and funding
|
selected publications
|
Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can
login
to make corrections and additions.
Most Recent
|
List All
UM1CA186709
(SHAPIRO, GEOFFREY I)
Mar 13, 2014 - Feb 28, 2023
NIH
Dana?Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)
Role: Co-Principal Investigator
R01CA090687
(SHAPIRO, GEOFFREY I)
Apr 1, 2001 - Feb 28, 2018
NIH
Cyclin-Dependent Kinase Inhibition During S Phase
Role: Principal Investigator
P50CA090578
(JOHNSON, BRUCE E.)
Apr 1, 2001 - Jun 30, 2015
NIH
Dana-Farber/Harvard Cancer Center SPORE in Lung Cancer
Role: Co-Principal Investigator
K08CA073700
(SHAPIRO, GEOFFREY I)
Jul 1, 1997 - Jun 30, 2000
NIH
IDENTIFICATION OF CYCLIN C ASSOCIATED PROTEINS
Role: Principal Investigator
Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can
login
to make corrections and additions.
Newest
|
Oldest
|
Most Cited
|
Most Discussed
|
Timeline
|
Field Summary
|
Plain Text
PMC Citations
indicate the number of times the publication was cited by articles in PubMed Central, and the
Altmetric
score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.)
Fields
are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication.
Translation
tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
Patterson-Fortin J
, Jadhav H, Pantelidou C, Phan T, Grochala C,
Mehta AK
,
Guerriero JL
,
Wulf GM
,
Wolpin BM
, Stanger BZ,
Aguirre AJ
,
Cleary JM
,
D'Andrea AD
,
Shapiro GI
. Polymerase ? inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer. Nat Commun. 2023 Mar 13; 14(1):1390.
PMID:
36914658
; PMCID:
PMC10011609
.
Citations:
Fields:
Bio
Biology
Sci
Science
Yamashita N
, Morimoto Y, Fushimi A, Ahmad R,
Bhattacharya A
, Daimon T, Haratake N, Inoue Y,
Ishikawa S
, Yamamoto M, Hata T, Akiyoshi S, Hu Q, Liu T, Withers H, Liu S,
Shapiro GI
, Yoshizumi T, Long MD,
Kufe D
. MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer. Mol Cancer Res. 2023 03 01; 21(3):274-289.
PMID:
36445328
; PMCID:
PMC9975675
.
Citations:
Fields:
Cel
Cell Biology
Mol
Molecular Biology
Neo
Neoplasms
Translation:
Humans
Cells
Ali LR
,
Garrido-Castro AC
, Lenehan PJ, Bollenrucher N, Stump CT,
Dougan M
, Goel S,
Shapiro GI
,
Tolaney SM
,
Dougan SK
. PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer. J Exp Med. 2023 Apr 03; 220(4).
PMID:
36688919
; PMCID:
PMC9884581
.
Citations:
Fields:
All
Allergy and Immunology
Med
Medicine (General)
Translation:
Animals
Keller RB, Mazor T,
Sholl L
,
Aguirre AJ
,
Singh H
,
Sethi N
, Bass A, Nagaraja AK, Brais LK, Hill E, Hennessey C, Cusick M, Del Vecchio Fitz C, Zwiesler Z, Siegel E, Ovalle A, Trukhanov P, Hansel J,
Shapiro GI
,
Abrams TA
,
Biller LH
,
Chan JA
,
Cleary JM
, Corsello SM,
Enzinger AC
,
Enzinger PC
,
Mayer RJ
,
McCleary NJ
,
Meyerhardt JA
,
Ng K
, Patel AK, Perez KJ, Rahma OE,
Rubinson DA
, Wisch JS,
Yurgelun MB
,
Hassett MJ
,
MacConaill L
, Schrag D,
Cerami E
,
Wolpin BM
,
Nowak JA
,
Giannakis M
. Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer. JCO Precis Oncol. 2023 01; 7:e2200342.
PMID:
36634297
; PMCID:
PMC9929103
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Patterson-Fortin J
,
Bose A
, Tsai WC, Grochala C, Nguyen H, Zhou J, Parmar K, Lazaro JB, Liu J, McQueen K,
Shapiro GI
,
Kozono D
,
D'Andrea AD
. Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant Cancers. Cancer Res. 2022 10 17; 82(20):3815-3829.
PMID:
35972384
; PMCID:
PMC9588747
.
Citations:
6
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Klein H, Mazor T, Siegel E, Trukhanov P, Ovalle A, Vecchio Fitz CD, Zwiesler Z, Kumari P, Van Der Veen B, Marriott E, Hansel J, Yu J, Albayrak A, Barry S, Keller RB,
MacConaill LE
,
Lindeman N
,
Johnson BE
,
Rollins BJ
, Do KT, Beardslee B,
Shapiro G
, Hector-Barry S, Methot J,
Sholl L
, Lindsay J,
Hassett MJ
,
Cerami E
. MatchMiner: an open-source platform for cancer precision medicine. NPJ Precis Oncol. 2022 Oct 06; 6(1):69.
PMID:
36202909
; PMCID:
PMC9537311
.
Citations:
2
da Costa AABA,
Chowdhury D
,
Shapiro GI
,
D'Andrea AD
,
Konstantinopoulos PA
. Targeting replication stress in cancer therapy. Nat Rev Drug Discov. 2023 01; 22(1):38-58.
PMID:
36202931
.
Citations:
2
Fields:
Dru
Drug Therapy
Pha
Pharmacology
Translation:
Humans
Cells
Pantelidou C, Jadhav H, Kothari A, Liu R,
Wulf GM
,
Guerriero JL
,
Shapiro GI
. STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer. NPJ Breast Cancer. 2022 Sep 06; 8(1):102.
PMID:
36068244
; PMCID:
PMC9448789
.
Citations:
1
French CA
, Cheng ML,
Hanna GJ
,
DuBois SG
, Chau NG, Hann CL, Storck S, Salgia R, Trucco M, Tseng J, Stathis A, Piekarz R, Lauer UM, Massard C, Bennett K, Coker S, Tontsch-Grunt U, Sos ML, Liao S,
Wu CJ
,
Polyak K
, Piha-Paul SA,
Shapiro GI
. Report of the First International Symposium on NUT Carcinoma. Clin Cancer Res. 2022 06 13; 28(12):2493-2505.
PMID:
35417004
; PMCID:
PMC9197941
.
Citations:
4
Fields:
Neo
Neoplasms
Translation:
Humans
Choudhury AD
, Higano CS, de Bono JS, Cook N, Rathkopf DE, Wisinski KB, Martin-Liberal J, Linch M, Heath EI, Baird RD, García-Carbacho J, Quintela-Fandino M, Barry ST, de Bruin EC, Colebrook S, Hawkins G, Klinowska T, Maroj B, Moorthy G, Mortimer PG, Moschetta M, Nikolaou M, Sainsbury L,
Shapiro GI
, Siu LL, Hansen AR. A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kß/d, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022 06 01; 28(11):2257-2269.
PMID:
35247924
; PMCID:
PMC9662946
.
Citations:
2
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Yamashita N
, Fushimi A, Morimoto Y,
Bhattacharya A
, Hagiwara M, Yamamoto M, Hata T,
Shapiro GI
, Long MD, Liu S,
Kufe D
. Targeting MUC1-C Suppresses Chronic Activation of Cytosolic Nucleotide Receptors and STING in Triple-Negative Breast Cancer. Cancers (Basel). 2022 May 24; 14(11).
PMID:
35681561
; PMCID:
PMC9179855
.
Citations:
4
Batalini F, Xiong N,
Tayob N
, Polak M, Eismann J, Cantley LC,
Shapiro GI
, Adalsteinsson V,
Winer EP
,
Konstantinopoulos PA
,
D'Andrea A
, Swisher EM,
Matulonis UA
,
Wulf GM
,
Mayer EL
. Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. Clin Cancer Res. 2022 04 14; 28(8):1493-1499.
PMID:
35149538
; PMCID:
PMC9066379
.
Citations:
5
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Raghavan S
, Winter PS, Navia AW,
Williams HL
, DenAdel A, Lowder KE, Galvez-Reyes J, Kalekar RL, Mulugeta N, Kapner KS, Raghavan MS, Borah AA, Liu N, Väyrynen SA, Costa AD, Ng RWS, Wang J, Hill EK, Ragon DY, Brais LK, Jaeger AM, Spurr LF,
Li YY
,
Cherniack AD
, Booker MA, Cohen EF, Tolstorukov MY, Wakiro I,
Rotem A
,
Johnson BE
, McFarland JM,
Sicinska ET
, Jacks TE, Sullivan RJ,
Shapiro GI
,
Clancy TE
,
Perez K
,
Rubinson DA
,
Ng K
,
Cleary JM
, Crawford L, Manalis SR,
Nowak JA
,
Wolpin BM
,
Hahn WC
,
Aguirre AJ
,
Shalek AK
. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell. 2021 12 09; 184(25):6119-6137.e26.
PMID:
34890551
; PMCID:
PMC8822455
.
Citations:
46
Fields:
Cel
Cell Biology
Translation:
Humans
Cells
Konstantinopoulos PA
,
Cheng SC
,
Supko JG
, Polak M, Wahner-Hendrickson AE, Ivy SP, Bowes B, Sawyer H, Basada P, Hayes M, Curtis J,
Horowitz N
,
Wright AA
,
Campos SM
,
Ivanova EV
,
Paweletz CP
, Palakurthi S,
Liu JF
,
D'Andrea AD
, Gokhale PC,
Chowdhury D
,
Matulonis UA
,
Shapiro GI
. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours. Br J Cancer. 2022 04; 126(7):1027-1036.
PMID:
34887522
; PMCID:
PMC8980096
.
Citations:
8
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Rubinson D
,
Wolpin BM
,
Warsofsky IS
,
Ryan DP
,
Perez K
, Rahma O,
Singh H
,
Yurgelun MB
,
Shapiro GI
,
Aguirre AJ
,
D'Andrea AD
,
Cleary JM
. Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report. J Gastrointest Oncol. 2021 Dec; 12(6):3133-3140.
PMID:
35070436
; PMCID:
PMC8748075
.
Citations:
2
Konstantinopoulos PA
, da Costa AABA,
Gulhan D
,
Lee EK
,
Cheng SC
, Hendrickson AEW,
Kochupurakkal B
,
Kolin DL
, Kohn EC,
Liu JF
,
Stover EH
, Curtis J,
Tayob N
, Polak M,
Chowdhury D
,
Matulonis UA
, Färkkilä A,
D'Andrea AD
,
Shapiro GI
. A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nat Commun. 2021 09 22; 12(1):5574.
PMID:
34552099
; PMCID:
PMC8458434
.
Citations:
7
Fields:
Bio
Biology
Sci
Science
Translation:
Humans
Cells
CT
Clinical Trials
Cleary JM
,
Wolpin BM
,
Dougan SK
,
Raghavan S
,
Singh H
,
Huffman B
,
Sethi NS
,
Nowak JA
,
Shapiro GI
,
Aguirre AJ
,
D'Andrea AD
. Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Clin Cancer Res. 2021 12 15; 27(24):6622-6637.
PMID:
34285063
; PMCID:
PMC8678153
.
Citations:
2
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Zhou J, Gelot C, Pantelidou C, Li A, Yücel H, Davis RE, Färkkilä A,
Kochupurakkal B
, Syed A,
Shapiro GI
, Tainer JA, Blagg BSJ, Ceccaldi R,
D'Andrea AD
. A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors. Nat Cancer. 2021 06; 2(6):598-610.
PMID:
34179826
; PMCID:
PMC8224818
.
Citations:
65
Translation:
Humans
Do KT,
Kochupurakkal B
, Kelland S, de Jonge A, Hedglin J, Powers A, Quinn N, Gannon C, Vuong L, Parmar K, Lazaro JB,
D'Andrea AD
,
Shapiro GI
. Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors. Clin Cancer Res. 2021 09 01; 27(17):4710-4716.
PMID:
34131002
.
Citations:
19
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Shapiro GI
, Wesolowski R, Devoe C, Lord S, Pollard J, Hendriks BS, Falk M, Diaz-Padilla I, Plummer R, Yap TA. Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. Br J Cancer. 2021 08; 125(4):520-527.
PMID:
34040174
; PMCID:
PMC8367944
.
Citations:
13
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Cleary JM
,
Raghavan S
, Wu Q,
Li YY
, Spurr LF, Gupta HV,
Rubinson DA
, Fetter IJ,
Hornick JL
,
Nowak JA
, Siravegna G,
Goyal L
, Shi L, Brais LK, Loftus M,
Shinagare AB
,
Abrams TA
,
Clancy TE
, Wang J, Patel AK, Brichory F, Vaslin Chessex A, Sullivan RJ, Keller RB, Denning S, Hill ER,
Shapiro GI
, Pokorska-Bocci A, Zanna C,
Ng K
, Schrag D, Jänne PA,
Hahn WC
,
Cherniack AD
,
Corcoran RB
,
Meyerson M
, Daina A, Zoete V, Bardeesy N,
Wolpin BM
. FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021 10; 11(10):2488-2505.
PMID:
33926920
; PMCID:
PMC8690974
.
Citations:
10
Fields:
Neo
Neoplasms
Translation:
Humans
Morel KL
, Sheahan AV, Burkhart DL,
Baca SC
, Boufaied N, Liu Y,
Qiu X
, Cañadas I, Roehle K, Heckler M, Calagua C, Ye H, Pantelidou C, Galbo P, Panja S, Mitrofanova A, Wilkinson S, Whitlock NC, Trostel SY, Hamid AA,
Kibel AS
,
Barbie DA
,
Choudhury AD
,
Pomerantz MM
, Sweeney CJ,
Long HW
,
Einstein DJ
,
Shapiro GI
,
Dougan SK
, Sowalsky AG, He HH,
Freedman ML
,
Balk SP
,
Loda M
, Labbé DP, Olson BM, Ellis L. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021 04; 2(4):444-456.
PMID:
33899001
; PMCID:
PMC8061902
.
Citations:
54
Translation:
Humans
Cells
Do KT, Manuszak C, Thrash E, Giobbie-Hurder A, Hu J, Kelland S, Powers A, de Jonge A,
Shapiro GI
, Severgnini M. Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors. Cancer Immunol Immunother. 2021 Oct; 70(10):2991-3000.
PMID:
33745032
.
Citations:
8
Fields:
All
Allergy and Immunology
Neo
Neoplasms
The
Therapeutics
Translation:
Humans
Adib E
, Klonowska K, Giannikou K, Do KT, Pruitt-Thompson S, Bhushan K, Milstein MI, Hedglin J, Kargus KE,
Sholl LM
, Tsuji J, Hyman DM, Sisk A,
Shapiro GI
, Vargas HA, Harding JJ, Voss MH, Iyer G,
Kwiatkowski DJ
. Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. Clin Cancer Res. 2021 07 15; 27(14):3845-3853.
PMID:
33727259
; PMCID:
PMC8282751
.
Citations:
12
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Branigan TB
,
Kozono D
,
Schade AE
, Deraska P, Rivas HG, Sambel L,
Reavis HD
,
Shapiro GI
,
D'Andrea AD
,
DeCaprio JA
. MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity. Cell Rep. 2021 03 02; 34(9):108808.
PMID:
33657372
; PMCID:
PMC7970065
.
Citations:
11
Fields:
Cel
Cell Biology
Mol
Molecular Biology
Translation:
Humans
Cells
Shapiro GI
, O'Mara E, Laskin OL, Gao L, Baird JD, Spiegel RJ, Kaushik D, Weetall M, Colacino J, O'Keefe K, Branstrom A, Goodwin E, Infante J, Bedard PL, Kong R. Pharmacokinetics and Safety of PTC596, a Novel Tubulin-Binding Agent, in Subjects With Advanced Solid Tumors. Clin Pharmacol Drug Dev. 2021 08; 10(8):940-949.
PMID:
33440067
.
Citations:
6
Fields:
Dru
Drug Therapy
Pha
Pharmacology
Translation:
Humans
CT
Clinical Trials
Singh H
,
Li YY
, Spurr LF,
Shinagare AB
, Abhyankar R, Reilly E, Brais LK, Nag A, Ducar MD, Thorner AR,
Shapiro GI
, Keller RB, Siletti C,
Clark JW
, Farago AF,
Lin JJ
,
Demetri GD
, Gujrathi R, Kulke MH,
MacConaill LE
,
Ligon AH
,
Sicinska E
,
Meyerson ML
,
Meyerhardt JA
,
Cherniack AD
,
Wolpin BM
,
Ng K
,
Giannakis M
, Hornick JL,
Cleary JM
. Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clin Cancer Res. 2021 03 15; 27(6):1695-1705.
PMID:
33414136
; PMCID:
PMC9063924
.
Citations:
10
Fields:
Neo
Neoplasms
Translation:
Humans
Mehta AK
, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, Lin JR, Hurst KE, de Oliveira Taveira M, Johnson NT,
Oldham WM
, Kalocsay M, Berberich MJ, Boswell SA, Kothari A, Johnson S,
Dillon DA
, Lipschitz M,
Rodig S
,
Santagata S
,
Garber JE
,
Tung N
, Yélamos J, Thaxton JE,
Mittendorf EA
,
Sorger PK
,
Shapiro GI
,
Guerriero JL
. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat Cancer. 2021 01; 2(1):66-82.
PMID:
33738458
; PMCID:
PMC7963404
.
Citations:
57
Translation:
Humans
Cells
Shapiro GI
, LoRusso P, Dowlati A, T Do K,
Jacobson CA
, Vaishampayan U, Weise A, Caimi PF, Eder JP,
French CA
, Labriola-Tompkins E, Boisserie F, Pierceall WE, Zhi J, Passe S, DeMario M, Kornacker M,
Armand P
. A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Br J Cancer. 2021 02; 124(4):744-753.
PMID:
33311588
; PMCID:
PMC7884382
.
Citations:
28
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Keenan TE, Li T,
Vallius T
,
Guerriero JL
,
Tayob N
,
Kochupurakkal B
, Davis J, Pastorello R, Tahara RK, Anderson L, Conway J, He MX, Shannon E, Godin RE,
Sorger PK
,
D'Andrea A
, Overmoyer B,
Winer EP
,
Mittendorf EA
,
Van Allen EM
,
Shapiro GI
,
Tolaney SM
. Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2021 02 15; 27(4):983-991.
PMID:
33257427
; PMCID:
PMC7887044
.
Citations:
13
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Li F,
Kozono D
, Deraska P,
Branigan T
, Dunn C,
Zheng XF
, Parmar K, Nguyen H,
DeCaprio J
,
Shapiro GI
,
Chowdhury D
,
D'Andrea AD
. CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress. Mol Cell. 2020 11 05; 80(3):410-422.e6.
PMID:
33108758
.
Citations:
13
Fields:
Cel
Cell Biology
Mol
Molecular Biology
Translation:
Humans
Animals
Cells
Do KT, O'Sullivan Coyne G, Hays JL,
Supko JG
, Liu SV, Beebe K, Neckers L, Trepel JB, Lee MJ, Smyth T, Gannon C, Hedglin J, Muzikansky A,
Campos S
, Lyons J, Ivy P, Doroshow JH, Chen AP,
Shapiro GI
. Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2020 12; 86(6):815-827.
PMID:
33095286
.
Citations:
6
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA,
Shapiro GI
, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020 09 24; 383(13):1207-1217.
PMID:
32955176
; PMCID:
PMC7571518
.
Citations:
423
Fields:
Med
Medicine (General)
Translation:
Humans
CT
Clinical Trials
Shapiro GI
, LoRusso P, Cho DC, Musib L, Yan Y, Wongchenko M, Chang I, Patel P, Chan IT, Sanabria-Bohorquez S, Meng RD, Bendell JC. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors. Invest New Drugs. 2021 02; 39(1):163-174.
PMID:
32737717
.
Citations:
4
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
CT
Clinical Trials
Tolaney SM
, Do KT, Eder JP, LoRusso PM,
Weekes CD
, Chandarlapaty S, Chang CW, Chen SC, Nazzal D, Schuth E, Brunstein F, Carrasco-Triguero M, Darbonne WC, Giltnane JM, Flanagan WM, Commerford SR, Ungewickell A,
Shapiro GI
, Modi S. A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors. Clin Cancer Res. 2020 11 01; 26(21):5588-5597.
PMID:
32694157
; PMCID:
PMC9899652
.
Citations:
3
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Konstantinopoulos PA
,
Cheng SC
, Wahner Hendrickson AE,
Penson RT
,
Schumer ST
, Doyle LA,
Lee EK
, Kohn EC, Duska LR, Crispens MA, Olawaiye AB, Winer IS, Barroilhet LM, Fu S, McHale MT, Schilder RJ, Färkkilä A,
Chowdhury D
, Curtis J, Quinn RS, Bowes B,
D'Andrea AD
,
Shapiro GI
,
Matulonis UA
. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020 07; 21(7):957-968.
PMID:
32553118
.
Citations:
52
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Weekes C
, Lockhart A, LoRusso P, Murray E, Park E, Tagen M, Singh J, Sarkar I, Mueller L, Dokainish H,
Shapiro G
, Burris H. A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors. Oncologist. 2020 10; 25(10):833-e1438.
PMID:
32311798
; PMCID:
PMC7543243
.
Citations:
10
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Cleary JM
,
Aguirre AJ
,
Shapiro GI
,
D'Andrea AD
. Biomarker-Guided Development of DNA Repair Inhibitors. Mol Cell. 2020 06 18; 78(6):1070-1085.
PMID:
32459988
.
Citations:
86
Fields:
Cel
Cell Biology
Mol
Molecular Biology
Translation:
Humans
Animals
Cells
Färkkilä A,
Gulhan DC
, Casado J, Jacobson CA, Nguyen H,
Kochupurakkal B
,
Maliga Z
,
Yapp C
, Chen YA, Schapiro D, Zhou Y, Graham JR, Dezube BJ, Munster P,
Santagata S
, Garcia E,
Rodig S
, Lako A,
Chowdhury D
,
Shapiro GI
,
Matulonis UA
,
Park PJ
, Hautaniemi S,
Sorger PK
, Swisher EM,
D'Andrea AD
,
Konstantinopoulos PA
. Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 05 18; 11(1):2543.
PMID:
32424117
.
Citations:
4
Fields:
Bio
Biology
Sci
Science
Morrison-Smith CD, Knox TM, Filic I, Soroko KM, Eschle BK, Wilkens MK, Gokhale PC, Giles F, Griffin A, Brown B,
Shapiro GI
, Zucconi BE,
Cole PA
, Lemieux ME,
French CA
. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734. Mol Cancer Ther. 2020 07; 19(7):1406-1414.
PMID:
32371576
.
Citations:
26
Fields:
Ant
Antineoplastic Agents
Translation:
Humans
Animals
Cells
Ricciuti B
, Recondo G, Spurr LF,
Li YY
, Lamberti G, Venkatraman D,
Umeton R
,
Cherniack AD
, Nishino M,
Sholl LM
,
Shapiro GI
,
Awad MM
, Cheng ML. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 08 01; 26(15):4135-4142.
PMID:
32332016
.
Citations:
58
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Färkkilä A,
Gulhan DC
, Casado J, Jacobson CA, Nguyen H,
Kochupurakkal B
,
Maliga Z
,
Yapp C
, Chen YA, Schapiro D, Zhou Y, Graham JR, Dezube BJ, Munster P,
Santagata S
, Garcia E,
Rodig S
, Lako A,
Chowdhury D
,
Shapiro GI
,
Matulonis UA
,
Park PJ
, Hautaniemi S,
Sorger PK
, Swisher EM,
D'Andrea AD
,
Konstantinopoulos PA
. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 03 19; 11(1):1459.
PMID:
32193378
.
Citations:
92
Fields:
Bio
Biology
Sci
Science
Translation:
Humans
Cells
CT
Clinical Trials
Cleary JM
, Calvo E, Moreno V,
Juric D
,
Shapiro GI
, Vanderwal CA, Hu B, Gifford M, Barch D, Roberts-Rapp L, Ansell PJ, Xiong H, Ocampo C, Tolcher AW. A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR. Invest New Drugs. 2020 10; 38(5):1483-1494.
PMID:
32189093
.
Citations:
6
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
CT
Clinical Trials
Waks AG
, Cohen O,
Kochupurakkal B
, Kim D, Dunn CE, Buendia Buendia J,
Wander S
, Helvie K, Lloyd MR, Marini L, Hughes ME, Freeman SS, Ivy SP, Geradts J,
Isakoff S
, LoRusso P, Adalsteinsson VA,
Tolaney SM
,
Matulonis U
, Krop IE,
D'Andrea AD
,
Winer EP
,
Lin NU
,
Shapiro GI
, Wagle N. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. Ann Oncol. 2020 05; 31(5):590-598.
PMID:
32245699
.
Citations:
50
Fields:
Neo
Neoplasms
Translation:
Humans
Cai MY, Dunn CE, Chen W,
Kochupurakkal BS
, Nguyen H, Moreau LA,
Shapiro GI
, Parmar K,
Kozono D
,
D'Andrea AD
. Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in Double-Strand Break End Resection. Cell Rep. 2020 02 18; 30(7):2402-2415.e5.
PMID:
32075772
.
Citations:
21
Fields:
Cel
Cell Biology
Mol
Molecular Biology
Translation:
Humans
Cells
Shaw AT
, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M,
Iafrate AJ
,
Shapiro GI
, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019 Jul; 30(7):1121-1126.
PMID:
31987379
.
Citations:
Clark JW
, Camidge DR, Kwak EL, Maki RG,
Shapiro GI
, Chen I, Tan W, Randolph S, Christensen JG, Ozeck M, Tang Y, Wilner KD, Salgia R. Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncol. 2020 Jan; 16(1):4289-4301.
PMID:
31778074
.
Citations:
4
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Chau NG, Ma C, Danga K, Al-Sayegh H,
Nardi V
,
Barrette R
,
Lathan CS
,
DuBois SG
,
Haddad RI
,
Shapiro GI
,
Sallan SE
, Dhar A, Nelson JJ,
French CA
. An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. JNCI Cancer Spectr. 2020 Apr; 4(2):pkz094.
PMID:
32328562
; PMCID:
PMC7165803
.
Citations:
37
Fields:
Neo
Neoplasms
Sullivan RJ, Hollebecque A,
Flaherty KT
,
Shapiro GI
, Rodon Ahnert J, Millward MJ, Zhang W, Gao L, Sykes A, Willard MD, Yu D, Schade AE, Crowe K, Flynn DL, Kaufman MD, Henry JR, Peng SB, Benhadji KA, Conti I,
Gordon MS
, Tiu RV, Hong DS. A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. Mol Cancer Ther. 2020 02; 19(2):460-467.
PMID:
31645440
.
Citations:
23
Fields:
Ant
Antineoplastic Agents
Translation:
Humans
Cells
CT
Clinical Trials
Rajkumar-Calkins AS,
Szalat R
, Dreze M, Khan I, Frazier Z, Reznichenkov E, Schnorenberg MR, Tsai YF, Nguyen H,
Kochupurakkal B
,
D'Andrea AD
,
Shapiro GI
, Lazaro JB,
Mouw KW
. Functional profiling of nucleotide Excision repair in breast cancer. DNA Repair (Amst). 2019 10; 82:102697.
PMID:
31499327
; PMCID:
PMC6815104
.
Citations:
7
Fields:
Bio
Biochemistry
Mol
Molecular Biology
Translation:
Humans
Cells
Parmar K,
Kochupurakkal BS
, Lazaro JB, Wang ZC, Palakurthi S, Kirschmeier PT, Yang C, Sambel LA, Färkkilä A, Reznichenko E,
Reavis HD
, Dunn CE, Zou L, Do KT,
Konstantinopoulos PA
,
Matulonis UA
,
Liu JF
,
D'Andrea AD
,
Shapiro GI
. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. Clin Cancer Res. 2019 10 15; 25(20):6127-6140.
PMID:
31409614
; PMCID:
PMC6801076
.
Citations:
56
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Shaw AT
, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M,
Iafrate AJ
,
Shapiro GI
, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019 07 01; 30(7):1121-1126.
PMID:
30980071
.
Citations:
137
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Shapiro GI
, LoRusso P, Kwak E, Pandya S, Rudin CM, Kurkjian C,
Cleary JM
, Pilat MJ, Jones S, de Crespigny A, Fredrickson J, Musib L, Yan Y, Wongchenko M, Hsieh HJ, Gates MR, Chan IT, Bendell J. Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors. Invest New Drugs. 2020 04; 38(2):419-432.
PMID:
31020608
.
Citations:
24
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
CT
Clinical Trials
Pantelidou C, Sonzogni O, De Oliveria Taveira M,
Mehta AK
, Kothari A, Wang D, Visal T, Li MK, Pinto J, Castrillon JA, Cheney EM, Bouwman P, Jonkers J, Rottenberg S,
Guerriero JL
,
Wulf GM
,
Shapiro GI
. PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. Cancer Discov. 2019 06; 9(6):722-737.
PMID:
31015319
.
Citations:
221
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Shaw A, Riely GJ, Bang YJ, Kim DW, Camidge DR,
Shapiro GI
, Usari T, Wang SC, Wilner K, Clark JW, Ou SI. Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001. Ann Oncol. 2019 Apr; 30 Suppl 2:ii48-ii49.
PMID:
32131252
.
Citations:
Konstantinopoulos PA
, Barry WT, Birrer M, Westin SN, Cadoo KA,
Shapiro GI
,
Mayer EL
, O'Cearbhaill RE, Coleman RL,
Kochupurakkal B
, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM,
D'Andrea AD
,
Winer E
,
Wulf GM
,
Matulonis UA
. Olaparib and a-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019 04; 20(4):570-580.
PMID:
30880072
; PMCID:
PMC7025391
.
Citations:
85
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Cornell L,
Wander SA
, Visal T,
Wagle N
,
Shapiro GI
. MicroRNA-Mediated Suppression of the TGF-ß Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance. Cell Rep. 2019 03 05; 26(10):2667-2680.e7.
PMID:
30840889
.
Citations:
45
Fields:
Cel
Cell Biology
Mol
Molecular Biology
Translation:
Humans
Animals
Zeng M, Kwiatkowski NP, Zhang T, Nabet B, Xu M, Liang Y, Quan C, Wang J, Hao M, Palakurthi S, Zhou S, Zeng Q, Kirschmeier PT, Meghani K, Leggett AL, Qi J,
Shapiro GI
,
Liu JF
,
Matulonis UA
, Lin CY,
Konstantinopoulos PA
, Gray NS. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. Elife. 2018 11 13; 7.
PMID:
30422115
.
Citations:
53
Fields:
Bio
Biology
Translation:
Humans
Animals
Cells
Hill SJ
, Decker B, Roberts EA,
Horowitz NS
,
Muto MG
,
Worley MJ
,
Feltmate CM
,
Nucci MR
, Swisher EM, Nguyen H, Yang C,
Morizane R
,
Kochupurakkal BS
, Do KT,
Konstantinopoulos PA
,
Liu JF
,
Bonventre JV
,
Matulonis UA
,
Shapiro GI
,
Berkowitz RS
,
Crum CP
,
D'Andrea AD
. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov. 2018 11; 8(11):1404-1421.
PMID:
30213835
; PMCID:
PMC6365285
.
Citations:
140
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Haines E, Chen T, Kommajosyula N, Chen Z, Herter-Sprie GS, Cornell L, Wong KK,
Shapiro GI
. Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer. Oncotarget. 2018 Aug 03; 9(60):31572-31589.
PMID:
30167080
.
Citations:
26
Fields:
Neo
Neoplasms
Aguirre AJ
,
Nowak JA
, Camarda ND, Moffitt RA,
Ghazani AA
, Hazar-Rethinam M,
Raghavan S
, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, Helvie K, Oliver N,
Babic A
, Da Silva A, Nadres B, Van Seventer EE, Shahzade HA, St Pierre JP,
Burke KP
,
Clancy T
,
Cleary JM
,
Doyle LA
,
Jajoo K
,
McCleary NJ
,
Meyerhardt JA
, Murphy JE,
Ng K
,
Patel AK
,
Perez K
,
Rosenthal MH
,
Rubinson DA
,
Ryou M
,
Shapiro GI
,
Sicinska E
,
Silverman SG
, Nagy RJ, Lanman RB, Knoerzer D, Welsch DJ,
Yurgelun MB
, Fuchs CS, Garraway LA,
Getz G
, Hornick JL,
Johnson BE
, Kulke MH,
Mayer RJ
, Miller JW,
Shyn PB
, Tuveson DA,
Wagle N
, Yeh JJ,
Hahn WC
,
Corcoran RB
,
Carter SL
,
Wolpin BM
. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111.
PMID:
29903880
.
Citations:
134
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Shapiro GI
, Kristeleit RS, Burris HA, LoRusso P, Patel MR, Drew Y, Giordano H, Maloney L, Watkins S, Goble S, Jaw-Tsai S, Xiao JJ. Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors. Clin Pharmacol Drug Dev. 2019 01; 8(1):107-118.
PMID:
29799676
.
Citations:
14
Fields:
Dru
Drug Therapy
Pha
Pharmacology
Translation:
Humans
CT
Clinical Trials
Bockorny B
, Rusan M, Chen W, Liao RG, Li Y, Piccioni F, Wang J, Tan L, Thorner AR, Li T, Zhang Y, Miao C, Ovesen T,
Shapiro GI
,
Kwiatkowski DJ
, Gray NS,
Meyerson M
, Hammerman PS, Bass AJ. RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade. Mol Cancer Ther. 2018 07; 17(7):1526-1539.
PMID:
29654068
; PMCID:
PMC6030474
.
Citations:
19
Fields:
Ant
Antineoplastic Agents
Translation:
Humans
Animals
Cells
Rabinowits G, Lezcano C,
Catalano PJ
, McHugh P, Becker H, Reilly MM, Huang J, Tyagi A,
Thakuria M
, Bresler SC,
Sholl LM
,
Shapiro GI
,
Haddad R
,
DeCaprio JA
. Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. Oncologist. 2018 07; 23(7):814-821.
PMID:
29445030
.
Citations:
12
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR,
Shapiro GI
, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M,
Flaherty K
,
Buchbinder E
, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discov. 2018 02; 8(2):184-195.
PMID:
29247021
.
Citations:
124
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Shapiro GI
. Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress in an Elusive Search. Cancer Cell. 2017 12 11; 32(6):721-723.
PMID:
29232548
.
Citations:
6
Fields:
Neo
Neoplasms
Translation:
Humans
Deng J, Wang ES,
Jenkins RW
, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR,
Ivanova E
,
Paweletz CP
, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE,
Lizotte PH
, Merlino AA,
Quinn MM
, Bufe LE,
Yang A
, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC,
Richards WG
, Lorch JH,
Parangi S
, Gunda V,
Boland GM
,
Bueno R
, Palakurthi S,
Freeman GJ
,
Ritz J
, Haining WN, Sharpless NE,
Arthanari H
,
Shapiro GI
,
Barbie DA
, Gray NS, Wong KK. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov. 2018 02; 8(2):216-233.
PMID:
29101163
; PMCID:
PMC5809273
.
Citations:
261
Fields:
Neo
Neoplasms
Translation:
Humans
Animals
Cells
Hai J, Liu S, Bufe L, Do K, Chen T, Wang X, Ng C, Li S, Tsao MS,
Shapiro GI
, Wong KK. Synergy of WEE1 and mTOR Inhibition in Mutant KRAS-Driven Lung Cancers. Clin Cancer Res. 2017 Nov 15; 23(22):6993-7005.
PMID:
28821559
; PMCID:
PMC5690829
.
Citations:
15
Fields:
Neo
Neoplasms
Translation:
Humans
Animals
Cells
Ben-Ami E, Barysauskas CM, Solomon S, Tahlil K, Malley R, Hohos M, Polson K, Loucks M, Severgnini M, Patel T, Cunningham A,
Rodig SJ
,
Hodi FS
,
Morgan JA
, Merriam P,
Wagner AJ
,
Shapiro GI
,
George S
. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer. 2017 Sep 01; 123(17):3285-3290.
PMID:
28440953
; PMCID:
PMC5762200
.
Citations:
76
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Shapiro GI
. The evolving role of cyclin-dependent kinase inhibitors in cancer management. Clin Adv Hematol Oncol. 2017 Mar; 15(3):174-177.
PMID:
28398270
.
Citations:
1